These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7805088)

  • 1. [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
    Roth J; Růzicka E; Mecír P
    Cas Lek Cesk; 1994 Nov; 133(21):665-7. PubMed ID: 7805088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine does not influence olfactory thresholds in Parkinson's disease.
    Roth J; Radil T; Růzicka E; Jech R; Tichý J
    Funct Neurol; 1998; 13(2):99-103. PubMed ID: 9626594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The apomorphine test in Parkinson's disease: diagnostic value].
    Linazasoro G
    Neurologia; 1993 Nov; 8(9):288-90. PubMed ID: 8297620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
    Eichhorn TE; Gasser T; Mai N; Marquardt C; Arnold G; Schwarz J; Oertel WH
    Mov Disord; 1996 May; 11(3):289-97. PubMed ID: 8723147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease.
    Louis ED; Goldman JE; Powers JM; Fahn S
    Mov Disord; 1995 Mar; 10(2):188-94. PubMed ID: 7753061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Apomorphine test in Parkinson disease--dose and corresponding parameters].
    Pinter MM; Helscher RJ; Sattler AP
    Wien Klin Wochenschr; 1993; 105(16):472-5. PubMed ID: 8212705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography.
    Dhawan V; Dhoat S; Williams AJ; Dimarco A; Pal S; Forbes A; Tobías A; Martinez-Martin P; Chaudhuri KR
    J Neurol Sci; 2006 Oct; 248(1-2):158-62. PubMed ID: 16780888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute dopaminergic responsiveness test in diagnosis of Parkinson's disease and Parkinsonian disorders].
    Li W; Feng T; Wang YJ; Lin JX; Xu XT
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(33):2347-9. PubMed ID: 19087697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M; Saéz D
    Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.